Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. - Test2 - elhamkhani - TriplyDB

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis.

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis.

http://www.wikidata.org/entity/Q39780220

about

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR Antifungal peptides: novel therapeutic compounds against emerging pathogens In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae.Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate.Antifungal peptides: potential candidates for the treatment of fungal infections.Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole.Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis Clinical pharmacokinetics of inhaled antimicrobials.The utility of a nebulised intra-tracheal rat model of invasive pulmonary aspergillosis.Isolation of a gene involved in 1,3-beta-glucan synthesis in Aspergillus nidulans and purification of the corresponding protein.Aerosolized Delivery of Antifungal Agents Nebulizer delivery of micafungin aerosols.

P2860

Q28343817-C53FBA97-D250-47A4-93A3-C214D7450E08 Q28344293-4EE41504-D9C6-4268-A1FB-71991014CC8F Q28344362-2340C6A6-01B1-4F94-8A5A-AC8F9BDC09D3 Q28361576-D7D226C3-8049-47F7-967B-41D211F6F035 Q28369443-7040170D-FFAF-4F2C-852B-F99725A9B3C0 Q28378977-8BDEF8AB-0794-4581-B93A-EB16103FE577 Q28379123-E7A5397D-0287-4E95-8397-2A736922588D Q30837205-0B56F8C4-6989-4194-BB31-67FC8DD6B756 Q33689767-ED0065D4-A49A-4465-8846-9004F1314F06 Q33983618-A996C7E7-45F0-43DC-9514-9471BCE203B2 Q34074702-23CE1046-C02C-4B4E-834E-97070E1554D3 Q34940421-34E63094-90D7-4308-B1A3-4CBA1F8AE587 Q35134300-11330F78-70C0-456B-BA7E-A613781FBE06 Q35138937-770ADDAC-2FF5-4209-AD1D-C2863BFCCD9F Q35636789-5CFF5F45-ED4D-4A3E-8E4D-A16F323D14BD Q38367260-0964EB94-C158-41EC-B531-32D024DE0F97 Q38938053-DC4F00E2-CD79-40A7-B409-F45761F7E9FE Q39842104-A5CAE654-D8BA-4913-873C-CBD240BD52D4 Q40522508-26D59234-FAD1-4D3C-B3E5-3440F03D410F Q51737733-369C7774-67C7-4554-B45C-08EBF2A67B76

P2860

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis.

http://www.wikidata.org/entity/Q39780220

description

1995 nî lūn-bûn

@nan

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

1995年论文

@zh

1995年论文

@zh-cn

name

Aerosol and parenteral pneumoc ...... el of pulmonary aspergillosis.

@en

Aerosol and parenteral pneumoc ...... el of pulmonary aspergillosis.

@nl

type

label

Aerosol and parenteral pneumoc ...... el of pulmonary aspergillosis.

@en

Aerosol and parenteral pneumoc ...... el of pulmonary aspergillosis.

@nl

prefLabel

Aerosol and parenteral pneumoc ...... el of pulmonary aspergillosis.

@en

Aerosol and parenteral pneumoc ...... el of pulmonary aspergillosis.

@nl

P1433

Q39780220-66B92F3C-D326-46ED-ABF5-D90D18132829

P1476

Q39780220-D3E46354-072C-465C-8A6D-B1D36F55C20C

P2093

Q39780220-4B216776-8DD2-4503-A3A2-7054838E98AE

Q39780220-4DDC963A-B66D-4A5A-BA81-0DD5F859C3E0

Q39780220-62E7641E-F178-40B9-9645-0D2DB4D43D3A

Q39780220-64BBB959-A4AD-4BE3-8AF6-FC0DC8C46E91

Q39780220-6A62D04E-5B54-433B-A0A5-DCC3E56AAF92

Q39780220-BC97C728-4C82-4FF4-ACC2-5C59F42C7205

Q39780220-E44D6882-89B9-41FA-AFD0-83AB5003F787

P2860

Q39780220-1535D193-4755-4AF4-AEC2-0B3BDA93C9A2

Q39780220-2D6E7AB2-75EC-4587-BDC2-000C330D5A18

Q39780220-3DA1E0DB-25AC-4506-A62E-D1BE995C20E8

Q39780220-4FB505A0-2709-4959-BA10-E66F8ACC5CBA

Q39780220-52960158-9DD2-4C9F-AD8A-098100C54188

Q39780220-5D56A7C1-8650-48ED-A94A-C1CA0531E97E

Q39780220-631A5F6A-62F8-4C85-ACDC-20112DA2CD67

Q39780220-76FDB578-CC98-4083-AF29-F14C0CE92DDA

Q39780220-789328FE-9CED-43B8-8C81-44DED81DA3B1

Q39780220-7B4A61BF-18FF-4394-8045-633F89404FB8

P304

Q39780220-6D13742C-26DD-4306-BAB3-2EE4CAE54D08

P31

Q39780220-C9B1C94E-060B-4651-8B11-0AF34AB79269

P356

Q39780220-52719FD2-66E6-4A80-AD0D-F329F81D24CE

P407

Q39780220-6BD5C33E-45DF-4B0E-AEC7-1479C2049502

P433

Q39780220-6E3EFDD0-4B7C-4BEB-9E8D-E657E975753E

P478

Q39780220-315DF2BF-B0D8-4D87-9223-56194B3C2BC9

P577

Q39780220-4D813CE3-56FF-4955-B411-10D879D636E9

P698

Q39780220-EC327BC8-96C7-49CA-8800-0F0076253461

P921

Q39780220-98140723-0382-4027-A8B7-A3E796525DB9

P932

Q39780220-DF7049CD-74A1-404A-B205-CF4A0CB588F2

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Aerosol and parenteral pneumoc ...... el of pulmonary aspergillosis.

@en

P2093

Armstrong D

http://www.w3.org/2001/XMLSchema#string

Bernard EM

http://www.w3.org/2001/XMLSchema#string

Douglas CM

http://www.w3.org/2001/XMLSchema#string

Dropinski J

http://www.w3.org/2001/XMLSchema#string

Edwards FF

http://www.w3.org/2001/XMLSchema#string

Kurtz MB

http://www.w3.org/2001/XMLSchema#string

Marrinan JA

http://www.w3.org/2001/XMLSchema#string

P2860

Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP)

Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors

Synergy between cilofungin and amphotericin B in a murine model of candidiasis

Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activity

New semisynthetic pneumocandins with improved efficacies against Pneumocystis carinii in the rat

In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373

Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives.

Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis

P304

1784-1789

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.39.8.1784

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

1995-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7486919

http://www.w3.org/2001/XMLSchema#string

P921

P932

162826

http://www.w3.org/2001/XMLSchema#string